Accelerating Clinical Trials Ltd Appoints New CEO
Accelerating Clinical Trials Ltd (ACT), a pioneer in accelerated clinical trial delivery, is delighted to announce the appointment of Dr Paul Sherrington as its new Chief Executive Officer, effective 1st September 2024.
Paul brings a wealth of expertise in haematological malignancies and a distinguished career that spans both academia and industry. Beginning his career researching cytogenetics and molecular genetics of leukaemia at the University of Cambridge and the MRC Laboratory of Molecular Biology, Paul later transitioned to the pharmaceutical and biotechnology sector. Most recently, he held pivotal roles at Celgene, where he chaired the European investigator-initiated trials programme and the external translational research programme. At Celgene, Paul collaborated extensively with internal research teams and external haematologists, focusing on advancing clinical and translational research in lymphoma, myeloma, and myeloid diseases.
“We are delighted to welcome Paul as our new CEO,” said Charles de Rohan, Chairman of Accelerating Clinical Trials Ltd. “His profound understanding of haematological malignancies, combined with his strategic leadership at Celgene, uniquely positions him to lead ACT into its next chapter of growth and innovation.”
Paul expressed enthusiasm about his new role, stating, “I am honoured to join Accelerating Clinical Trials Ltd and look forward to leveraging my experience to drive advancements in clinical trial efficiencies and ultimately improve patient outcomes.”
Paul succeeds Mercia Page, to whom ACT express profound thanks for her pivotal role in establishing the company over the past three years and are very pleased that she continues with the Company as a Non-Executive Director.
Professor Charlie Craddock CBE, founder of ACT commented “ACT represents a transformative clinical trials delivery vehicle for the UK haemato-oncology community. By funding national trials acceleration networks linked to a hub capable of delivering registration-standard data, ACT provides an integrated proposition highly attractive to the global pharmaceutical sector, allowing UK patients to access innovative drug, transplant and cellular therapies through practice-informing clinical trials as swiftly as possible”.
About Accelerating Clinical Trials Ltd: New drug, transplant and cellular therapy trials are transforming the outcomes of patients with haematological malignancies. ACT was established to provide a sustainable infrastructure for conducting and accelerating specialised haemato-oncology trials in the UK, with diverse minds driving change. We aspire to maximise the benefit of our portfolio of clinical trials for blood cancer patients by embedding genomics, diagnostics, and discovery science working with world class UK translational scientists alongside clinical research. We provide rapid delivery of a wide portfolio of blood cancer studies, from new drug and combination studies to stem cell transplant and cellular therapy trials. We offer rapid delivery of both investigator-initiated and industry-sponsored clinical trials to registrational standards.
For media inquiries or further information, please contact: Samantha Campbell, Accelerating Clinical Trials Ltd on info@act4patients.com